Member Info for Blownitalready

Not sure if this is what you're asking for guys...but this treatment is in very early stages of development.

https://www.dailymail.com/health/article-15865365/Wonder-pill-shrink-tumours-six-cancers.html

Continuing discussions with multiple parties on potential partnering of first, second and third generation assets.

👍

NurseSteve -

Enhertu® is a registered trademark of Daiichi Sankyo Company, Limited and AstraZeneca. Datroway® is a registered trademark of Daiichi Sankyo Company, Limited

Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026

LONDON and PHILADELPHIA - May 6, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, will today present two new developments at its Science Day 2026 event.

The Company is presenting comparative analyses of pre|CISION® payload delivery via one of its programs, AVA6103, compared with now two approved Antibody-Drug Conjugates (ADCs).It is also presenting updated in vivo studies of the dual payload delivery system in another program, AVA6207.

Christina Coughlin, CEO of Avacta, commented:

"These presentations further underline the potential of our unique pre|CISION® technology to improve treatment options for cancer patients.

"Providing data analysis of two ADCs, including Enhertu®, as part of the AVA6103 program, further demonstrates the alignment of the ADC mechanism and highlights the critical advantages of our pre|CISION® delivery directly to the tumor with higher selectivity, regardless of the ADC target.

"The data with our pre|CISION technology to deliver dual payloads has now demonstrated for the first time an efficacy advantage over single payload ADCs in a FAP-low and HER2-positive patient-derived cancer model.

"We continue to build momentum and enhance our IP - at a pace that we are confident exceeds industry norms."

AVA6103: The new data analyses in the AVA6103 program comparing pre|CISION® FAP-cleavable exatecan delivery with those of leading marketed ADCs have been extended to Datroway®, an ADC targeting the TROP2 antigen, as well as Enhertu® an ADC targeting the HER2 antigen.

Details of these studies:

· All three of these drugs (AVA6103, Enhertu® and Datroway®) feature tumor-targeted delivery of topoisomase I inhibitors (exatecan or deruxtecan) and these comparisons are designed to address the differences in the payload delivery and control for the differences in cancer models

· The delivery kinetics of exatecan (derived from AVA6103) and deruxtecan (derived from Enhertu® or Datroway®) demonstrate more rapid tumor penetration of released exatecan from AVA6103 (Tmax of minutes, AVA6103 versus Tmax >24 hours, Enhertu® or Datroway®) and higher maximal concentration (Cmax) of released payload in the tumor with differences observed of over 1-log

· The tumor selectivity index (TSI) is a measure of the overall exposure (area under the curve, AUC) in the tumor vs. the bloodstream (TSI = AUC[tumor/plasma]) which is at least 3 times higher with released exatecan from AVA6103 than either released deruxtecan from Enhertu® or Datroway®

· The Company is planning to publish these findings at an upcoming academic meeting and in a peer-reviewed journal

AVA6207: The in vivo data in th

Alexander Spira MD, PhD, FACP, FASCO, Co-Director, Virginia Cancer Specialists (VCS) Research Institute and one of the lead investigators of the trial, commented:

"Targeting a potent topoisomerase I inhibitor specifically to the tumor, and thereby minimizing damage to healthy cells, potentially marks a significant advance in cancer care. We're excited to work with Avacta and join this Phase 1 trial for AVA6103 and to bring this cutting-edge approach into reality and improve treatment options for patients in need.

With the pre|CISION® platform reaching approximately 90% of solid tumors, it opens up so many opportunities in the clinic and we are happy to work with Avacta on this exciting new approach."

Directors buying is always a major positive 👍

Https://www.londonstockexchange.com/news-article/AVCT/result-of-oversubscribed-fundraise/17522582

Https://www.fiercebiotech.com/biotech/analyst-china-no-longer-bargain-basement-biotech-acquisitions

BRV - your takeover estimate is way too low.....adding a zero on the end would still be too low !

Https://www.fiercebiotech.com/biotech/gilead-inks-78b-arcellx-buyout-steer-car-t-jj-showdown

I liked this small sentence.....

The historic maximum dosing limit which is based on the patient's exposure to released (free) doxorubicin, has been removed in the clinical trial following the collection of highly favorable safety data from the faridoxorubicin program and observation of patients receiving the highest cumulative doses for prolonged periods.

History is being made here ✅

Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosing levels. These two developments underscore the growing confidence from investigators and regulators in the tolerability profile of faridoxorubicin and should support a smooth transition to future efficacy studies.

The historic maximum dosing limit which is based on the patient's exposure to released (free) doxorubicin, has been removed in the clinical trial following the collection of highly favorable safety data from the faridoxorubicin program and observation of patients receiving the highest cumulative doses for prolonged periods. Dosing in the Phase 1 clinical trial escalated to a dose of nearly 4x the conventional dose of doxorubicin and the maximum cumulative exposure of released doxorubicin was increased to 550 mg/m2 during the trial with no severe cardiac toxicity observed.

NICE 👌

Purpose of the J.P. Morgan healthcare Conference ?

This flagship event is the world's largest and most influential healthcare investment gathering, bringing together global industry leaders, rapidly growing biopharma and medtech companies, cutting-edge technology innovators, and the investment community.

IFA90- Thanks for the reminder

The J.P. Morgan Healthcare Conference is the world's largest and most significant annual healthcare investment symposium, bringing together industry leaders, investors, innovators, and emerging companies in San Francisco from January 12–15, 2026, for networking, deal-making, and discussions on healthcare trends, innovation, and future opportunities. It's an invitation-only event focused on connecting stakeholders across pharma, biotech, medical tech, and healthcare services to discuss scientific breakthroughs and business strategy.

Christina Coughlin, M.D., Ph.D., Chief Executive Officer of Avacta, said:

"The development of the first dual payload peptide drug conjugate platform marks a major leap forward in oncology therapy. This significantly extends the potential of our innovative pre|CISION® platform by implementing combination cancer therapy in a single medicine.

"This new IP builds on the success of our FAP-EXd (AVA6103) program, where we invented a sustained release delivery mechanism with the platform. Our novel implementation of the platform extends this observation to now release two drugs from one pre|CISION® molecule. The key factor here is our ability to target the tumor with a cytotoxic drug and attack the known resistance mechanism all in one cancer medicine. By building on the prior knowledge, we have now extended the reach to highly-resistant cancers by targeting key resistance mechanisms.

This drug combination approach demonstrates the value we are building in our proprietary pre|CISION® technology by further underlining its flexibility and unique potential to expand into novel oncology therapeutic approaches.

Reminder from the previous RNS - words from the CEO

"We look forward to presenting the full data at the 2025 EORTC-NCI-AACR Symposium later this month."

Asked GROK about it ....

How Significant Is This Data?

High Significance for Avacta and the Field: Platform Validation: This is the first clinical proof-of-concept for pre|CISION®, demonstrating targeted activation in humans. It de-risks the platform for future assets (e.g., AVA6103, a topo I inhibitor PDC entering Phase 1 in Q1 2026) and dual-payload PDCs (data at EORTC-NCI-AACR next week). Pre|CISION could enable "naked" chemo repurposing with better safety, potentially revolutionizing combos in immuno-oncology.

Clinical Impact: In rare, aggressive cancers like SGC (high unmet need, no approved therapies), AVA6000's near-doubling of PFS and clean safety profile positions it as a potential registrational candidate. Phase 1b expansion data (SGC cohort) expected by year-end 2025 could support accelerated approval paths.

Https://avacta.com/avacta-therapeutics-presents-compelling-phase-1a-data-for-faridoxorubicin-and-the-precision-platform-at-the-european-society-of-medical-oncology-annual-congress/

All credits go to Allie.....great piece. 👏👏

Part 3

•The Bigger Picture: Platform Logic + Market Timing

Most of the market still prices #AVCT as if it were a single asset biotech. In reality, both biologically and economically, it’s starting to function more like a delivery operating system, a platform that can host multiple cancer drugs. In oncology, the ability to deploy multiple therapeutic “warheads” within a single activation logic is more than clever chemistry; it’s infrastructure, the foundation of how next generation treatments will be built. That’s why comparable conjugate platforms have attracted escalating premiums long before late stage clinical data: they create a scalable delivery chassis others can plug into. The emerging pattern is a fusion of molecular versatility, tumour specific activation, and modular conjugation chemistry working together inside one IP framework. Each of those elements would be investable on its own; together, they define a category pharma is racing to control.

Speed builds headlines; precision builds empires

Part 2

•The Strategic Meaning Beyond One RNS

Pharma will read this RNS as a technological claim: preCISION has demonstrated adaptive evolution.

Investors should read it as strategic maturity a company now structurally, scientifically, and financially positioned to engage on its own terms.

The upcoming catalysts represent momentum milestones. Dual payload validation redefines preCISION as combination therapy infrastructure; once ESMO and SGC reinforce AVA6000’s clinical durability, the narrative shifts from hypothesis to thesis, and from validation risk to value realisation.